In terms of the antigenic landscape, the consistent factor for neoplastic progression of BE is abnormal p53 IHC staining, and a recent study with p53 staining in two cohorts, in 561 patients with and without progression, regardless of the diagnosis of dysplasia in retrospective and prospective cohorts [35], used methods similar to those used in our study. The gene discussed is TP53; the disease is dysplasia.